











# ADVANCE Course on Cell and Gene Therapies 2025

February 24 – 28, 2025

Co-organized by
ISTITUTO SUPERIORE DI SANITÀ
Department of Oncology and Molecular Medicine

and

#### TAKIS BIOTECH ROMA

Within the Project "Rome Technopole" PNRR-NextGenerationEU n. ECS 00000024, Mission 4 Education and Research, Component 2 From Research to Enterprise, Investment. 1.5 Creation and strengthening of "Innovation ecosystems for sustainability"

N° ID: 136C24 P

### Rationale

The 5-day course will cover all the aspects related to Advanced Therapy Medicinal Products (ATMPs), one of the most promising and challenging therapies. The course aims at preparing the new generation of scientists on ATMP: from preclinical development phase to clinical and regulatory requirements, the course will prepare the attendants to overcome critical issues of the whole cycle of ATMP development. Moreover, during the course specific session will be held on funding scheme and facilitating programs specifically available for ATMP.

The course grounds on the experience of the now concluded Erasmus+ ADVANCE programme promoted and coordinated by the non-profit European Research Infrastructure Consortium EATRIS, the European Infrastructure for Translational Medicine. Given the remarkable success of past editions, a decision was made by the Consortium to carry forward this educational course within the project "Rome Technopole".

#### Aim and objectives

The aim of the course is to prepare students and early- career scientists from Italy and Europe to the scientific and regulatory principles fundamental for the development of ATMP through frontal lessons, held by leaders in the field, and group assignments. The program includes the visit to biotechnological facilities and networking events.

### Specific objectives

At the end of the course, the participants will:

- 1. Have a broader overview of the issues that have to be overcome in ATMP development, grounding on stronger quality of knowledge, skills and competences;
- 2. Know available tools, research infrastructures, and funding schemes that can facilitate the development of novel ATMP:
- 3. Rely on stronger regulatory knowledge needed for the clinical development phase and marketing authorization.

#### **Didactic method**

Reports/lessons, exercises in small groups, interactive trainings and discussions.















### Provider N.2224

### **PROGRAMME**

### Monday 24 February 2025

### Preclinical and Clinical Development

Discussion and Daily Wrap up

Chair: Lucia Gabriele, Luciano Castiello		
9.00	Registration and welcome	
9.30	Introduction from the attendees	
10.30	1 <sup>st</sup> Lecture - Scientific basis and assessment of ATMPs  Janja Zupan	
11.00	Coffee break	
11.30	2 <sup>nd</sup> Lecture - Dual CART cells for Multiple Myeloma: from bench to bedside <b>Tuna Mutis</b>	
12.00	3 <sup>rd</sup> Lecture - Bridging the gap: from research protocols to GMP standards in clinical trials Anna Pasetto	
12.30	4 <sup>th</sup> Lecture - Clinical ATMP development Graziella Pellegrini	
13.00	Lunch	
14.15	Assignments	
14.30	Working groups	
15.45	Coffee break	















### Provider N.2224

### **Tuesday 25 February 2025**

### Manufacturing and Regulatory

Chair: Franca Moretti, Eleonora Aricò		
9.00	Daily introduction	
9.15	1st Lecture - ATMP manufacturing challenges Luciano Castiello	
9.45	2 <sup>nd</sup> Lecture – QTTP in ATMP development  Michela Gabaldo	
10.15	3 <sup>rd</sup> Lecture - Cell and gene therapies versus monoclonal antibodies; are we facing the same challenges after 40 years?  Massimo Dominici	
10.45	Coffee break	
11.15	4th Lecture – ATMP Hospital Exemption; regulatory aspects and evaluation of the clinical setting  Maria Francesca Cometa - Alessandra Ambrosone	
11.45	5 <sup>th</sup> Lecture - New European regulation on HTA: objectives and contents for ATMPs <b>To be defined</b>	
12.15	6 <sup>th</sup> Lecture - ATMP, regulatory aspects from clinical trials to authorization <b>Mauro Biffoni</b>	
12.45	Lunch	
13.45	GMP Facility tour	
16.15	Discussion and Daily Wrap up	















### Wednesday 26 February 2025

### New frontiers and Business in ATMP development

### Chair: Franca Moretti, Francesca Capone

9.00	Daily introduction
9.15	1st Lecture - ATMPs and Business Development Luigi Aurisicchio
9.55	2 <sup>nd</sup> Lecture - Supporting new ideas: non dilutive funding Lazio Innova
10.35	Coffee break
11.05	3 <sup>rd</sup> Lecture - Veterinary ATMP Antonella Conforti
11.45	4 <sup>th</sup> Lecture - ATMPs: Life cycle and opportunities Riccardo Palmisano
12.25	Lunch
15.00	Tour
19.00	Workshop dinner















### Thursday 27 February 2025

### ATMP Automation, Digitalization, and Training

### Chair: Luciano Castiello, Luigi Aurisicchio

	, 3
9.00	Daily introduction
9.15	1 <sup>st</sup> Lecture - Automation of Quality Control assays for ATMP batch release and characterization  Massimo Bocchi
9.55	2 <sup>nd</sup> Lecture - Real-time monitoring and control for dynamic manufacturing process <b>Paolo Gabaldi</b>
10.35	Coffee break
11.05	3 <sup>rd</sup> Lecture/Activity - Virtual creation of a GMP laboratory <b>Giancarlo De Matthaeis</b>
11.45	4th Lecture - ATMPs Biotech Academy Leonardo Sibilio
12.45	Lunch
13.45	Group Work
15.15	Coffee break
15.45	Group Work
16.15	Discussion and Daily Wrap up















### Friday 28 February 2025

### ATMP Reimbursement and Perspectives

### Chair: Lucia Gabriele, Luigi Aurisicchio

Chair: Luc	ia Gabriele, Luigi Aurisicchio
9.00	Daily introduction
9.15	Ist Lecture - Pricing and reimbursement mechanisms for ATMPs  Juan Carlos Rejon-Parrilla
9.45	2 <sup>nd</sup> Lecture - The role of EATRIS in developing the next generation of ATMPs <b>David Morrow</b>
10.15	Presentation, Examination, Evaluation – I <sup>st</sup> part
11.15	Coffee break
11.45	Presentation, Examination, Evaluation – 2 <sup>nd</sup> part
12.30	Wrap up and Farewell
3	















### TRAINERS and TUTORS

**Alessandra Ambrosone** - National Centre for Drug Research and Evaluation, Italian Institute of Health (ISS), Rome

Eleonora Aricò - Core Facilities, Italian Institute of Health (ISS), Rome

Luigi Aurisicchio - Takis; EvviVax; NeoMatrix; Vitares; Assobiotec; Rome Technopole, Rome

Mauro Biffoni - Department of Oncology and Molecular Medicine, Italian Institute of Health (ISS), Rome Massimo Bocchi - Cellply, Bologna

**Francesca Capone** - Research Coordination and Promotion Service, Italian Institute of Health (ISS); Italian Advanced Translational Research Association (A IATRIS), Rome

Luciano Castiello - Core Facilities, Italian Institute of Health (ISS); Italian Advanced Translational Research Association (A IATRIS), Rome

Maria Francesca Cometa - National Centre for Drug Research and Evaluation, Italian Institute of Health (ISS), Rome

Antonella Conforti - EvviVax, Rome

Giancarlo De Matthaeis – Labozeta, Rome

**Massimo Dominici** - Department of Oncology and Hematology Azienda Ospedaliero-Universitaria di Modena, Modena

Michela Gabaldo - EVOTEC, Fondazione Telethon, Milan

Paolo Gabaldi - Merck, Milan

Lucia Gabriele - Department of Oncology and Molecular Medicine, Italian Institute of Health (ISS); Italian Advanced Translational Research Association (A IATRIS), Rome

**Franca Moretti** - Research Coordination and Promotion Service, Italian Institute of Health (ISS); Italian Advanced Translational Research Association (A IATRIS), Rome

David Morrow - EATRIS Translational Medicine and Drug Development, Amsterdam

Tuna Mutis - Amsterdam University Medical Centers, Amsterdam

Anna Pasetto - Department of Oncology, Oslo University Hospital, Oslo

Riccardo Palmisano - Innova Vector Srl, Pozzuoli, Naples

**Graziella Pellegrini -** Centre for Regenerative Medicine, University of Modena and Reggio Emilia, Modena

**Juan Carlos Rejon-Parrilla** - HTA and Health Policy Researcher at Andalusian Regional Department of Health (area of HTA, AETSA), Seville

**Leonardo Sibilio** - Biotech Academy, Rome; BetaPro Consulting, Rome **Janja Zupan** - Faculty of Pharmacy, University of Ljubljana, Ljubljana

### **Scientific Director**

LUCIA GABRIELE

Department of Oncology and Molecular Medicine Italian Institute of Health (ISS), Rome

LUIGI AURISICCHIO Takis Biotech S.r.l., Rome

### **Scientific Secretariat**

Francesca Capone, Tel. (+39)0649906839; E-mail: <a href="mailto:francesca.capone@iss.it">francesca.capone@iss.it</a> Franca Moretti, Tel. (+39)0649906830; E-mail: <a href="mailto:franca.moretti@iss.it">franca.moretti@iss.it</a>

Research Coordination and Promotion Service, Italian Institute of Health (ISS), Rome















LUCIANO CASTIELLO, Tel. (+39)0649906080; E-mail: <u>luciano.castiello@iss.it</u> LOREDANA LE PERA, Tel. (+39)0649902708; E-mail: <u>loredana.lepera@iss.it</u> Core Facilities Technical-Scientific Service, Italian Institute of Health (ISS), Rome

### **Organizational Secretariat**

MARIANGELA FONTANA, Tel. (+39) 0649906593 e-mail: mariangela.fontana@iss.it

IRENE CANINI, Tel. (+39)06 49903590 e-mail: <a href="mailto:irene.canini@iss.it">irene.canini@iss.it</a>
SARA GUALDI, Tel. (+39)06 49903201 e-mail: <a href="mailto:sara.gualdi@iss.it">sara.gualdi@iss.it</a>
SIMONA DONATI, Tel. (+39)06 49903289 e-mail: <a href="mailto:simona.donati@iss.it">simona.donati@iss.it</a>

Department of Oncology and Molecular Medicine, Italian Institute of Health (ISS), Rome

UGO VISCONTI, Tel. (+39) 0649903711 e-mail: ugo.visconti@iss.it

Research Coordination and Promotion Service, Italian Institute of Health (ISS), Rome

ANNA FERRIGNO E-mail: ferrigno@takis.it

Takis Biotech S.r.l., Rome

#### **Technical Moderator**

STEFANO GUIDA, E-mail: stefano.guida@iss.it

Dept. of Oncology and Molecular Medicine, Italian Institute of Health (ISS), Rome

### **GENERAL INFORMATION**

#### Venue

Italian Institute of Health (ISS), Aula Marotta, Viale del Castro Laurenziano 10 – Rome, Italy

### Official language

The official language is English.

### Registration and attendance

To register, complete and send the form available at the following link by 30/11/2024: <u>Application Form</u>. Actual attendance at the event will be verified by recording entry and exit in the appropriate attendance register. Participation in the event is free. Travel and accommodation expenses are the responsibility of the participant.

<u>Maximum 30 attendees will be selected</u>. Ten attendees will be priority selected within the founder partner of Rome Technopole.

#### Selection

Participants will be selected according to their CVs and motivation letter. Selected participants will be notified by 10/12/2024 and have to confirm participation by 15/12/2024.

### Learning assessment















Learning outcomes will be assessed through a practical simulation and by filling out a multiple-choice questionnaire on the last day of the course. This final test is compulsory for all participants to obtain the certificate of attendance.

#### Satisfaction questionnaire

At the end of the course, all participants should complete a quality assessment survey.

### This event does not provide any CME credits.

#### Certification

Attendance certificates indicating the hours of training will be issued on request to participants who complete at least 80% of the course and successfully pass the final test.

For any further information, please contact the Scientific Secretariat or send an email at advance.atmp@iss.it.

Event produced with an unconditional grant from Merck, Labozeta, CellPly, and Vitares

[Firma elettronica del Presidente]

